Close Menu

Sirius Genomics

Vancouver, Canada-based Sirius Genomics is using arrays to develop a test to identify individuals who respond to the hormone vasopressin and similar compounds for the treatment of septic shock.

The two firms will partner to develop diagnostics to identify individuals who respond well to Vasopressin and other compounds for the treatment of septic shock and related conditions.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Pairings: Jun 30, 2010

Premium

Kamran Alam, Stan Lapidus

Pairings: Dec 9, 2009

Premium

Chris Wagner, Brad Popovich, Jorge Garces, Greg Hamilton, Nick Williams, Darren Hall

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

Sirius will work with a system of 37 hospitals to test biomarkers for severe sepsis drug response.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.